BACKGROUND: Sudden infant death syndrome (SIDS) is a leading cause of death during the first 6 months after birth. About 5% to 10% of SIDS may stem from cardiac channelopathies such as long-QT syndrome. We recently implicated mutations in alpha1-syntrophin (SNTA1) as a novel cause of long-QT syndrome, whereby mutant SNTA1 released inhibition of associated neuronal nitric oxide synthase by the plasma membrane Ca-ATPase PMCA4b, causing increased peak and late sodium current (I(Na)) via S-nitrosylation of the cardiac sodium channel. This study determined the prevalence and functional properties of SIDS-associated SNTA1 mutations. METHODS AND RESULTS: Using polymerase chain reaction, denaturing high-performance liquid chromatography, and DNA sequencing of SNTA1's open reading frame, 6 rare (absent in 800 reference alleles) missense mutations (G54R, P56S, T262P, S287R, T372M, and G460S) were identified in 8 (approximately 3%) of 292 SIDS cases. These mutations were engineered using polymerase chain reaction-based overlap extension and were coexpressed heterologously with SCN5A, neuronal nitric oxide synthase, and PMCA4b in HEK293 cells. I(Na) was recorded using the whole-cell method. A significant 1.4- to 1.5-fold increase in peak I(Na) and 2.3- to 2.7-fold increase in late I(Na) compared with controls was evident for S287R-, T372M-, and G460S-SNTA1 and was reversed by a neuronal nitric oxide synthase inhibitor. These 3 mutations also caused a significant depolarizing shift in channel inactivation, thereby increasing the overlap of the activation and inactivation curves to increase window current. CONCLUSIONS: Abnormal biophysical phenotypes implicate mutations in SNTA1 as a novel pathogenic mechanism for the subset of channelopathic SIDS. Functional studies are essential to distinguish pathogenic perturbations in channel interacting proteins such as alpha1-syntrophin from similarly rare but innocuous ones.
BACKGROUND:Sudden infant death syndrome (SIDS) is a leading cause of death during the first 6 months after birth. About 5% to 10% of SIDS may stem from cardiac channelopathies such as long-QT syndrome. We recently implicated mutations in alpha1-syntrophin (SNTA1) as a novel cause of long-QT syndrome, whereby mutant SNTA1 released inhibition of associated neuronal nitric oxide synthase by the plasma membrane Ca-ATPase PMCA4b, causing increased peak and late sodium current (I(Na)) via S-nitrosylation of the cardiac sodium channel. This study determined the prevalence and functional properties of SIDS-associated SNTA1 mutations. METHODS AND RESULTS: Using polymerase chain reaction, denaturing high-performance liquid chromatography, and DNA sequencing of SNTA1's open reading frame, 6 rare (absent in 800 reference alleles) missense mutations (G54R, P56S, T262P, S287R, T372M, and G460S) were identified in 8 (approximately 3%) of 292 SIDS cases. These mutations were engineered using polymerase chain reaction-based overlap extension and were coexpressed heterologously with SCN5A, neuronal nitric oxide synthase, and PMCA4b in HEK293 cells. I(Na) was recorded using the whole-cell method. A significant 1.4- to 1.5-fold increase in peak I(Na) and 2.3- to 2.7-fold increase in late I(Na) compared with controls was evident for S287R-, T372M-, and G460S-SNTA1 and was reversed by a neuronal nitric oxide synthase inhibitor. These 3 mutations also caused a significant depolarizing shift in channel inactivation, thereby increasing the overlap of the activation and inactivation curves to increase window current. CONCLUSIONS: Abnormal biophysical phenotypes implicate mutations in SNTA1 as a novel pathogenic mechanism for the subset of channelopathic SIDS. Functional studies are essential to distinguish pathogenic perturbations in channel interacting proteins such as alpha1-syntrophin from similarly rare but innocuous ones.
Authors: P J Schwartz; S G Priori; R Dumaine; C Napolitano; C Antzelevitch; M Stramba-Badiale; T A Richard; M R Berti; R Bloise Journal: N Engl J Med Date: 2000-07-27 Impact factor: 91.245
Authors: Michael J Ackerman; David J Tester; Gregg S Jones; Melissa L Will; Christopher R Burrow; Mark E Curran Journal: Mayo Clin Proc Date: 2003-12 Impact factor: 7.616
Authors: Eric Lizotte; M Juhani Junttila; Marie Pierre Dube; Kui Hong; Begona Benito; Marc DE Zutter; Stefan Henkens; Andrea Sarkozy; Heikki V Huikuri; Jeffrey Towbin; Matteo Vatta; Pedro Brugada; Josep Brugada; Ramon Brugada Journal: J Cardiovasc Electrophysiol Date: 2009-06-22
Authors: Jianding Cheng; David J Tester; Bi-Hua Tan; Carmen R Valdivia; Stacie Kroboth; Bin Ye; Craig T January; Michael J Ackerman; Jonathan C Makielski Journal: Physiol Genomics Date: 2011-03-08 Impact factor: 3.107
Authors: Jianding Cheng; Carmen R Valdivia; Ravi Vaidyanathan; Ravi C Balijepalli; Michael J Ackerman; Jonathan C Makielski Journal: J Mol Cell Cardiol Date: 2013-03-26 Impact factor: 5.000
Authors: Wenxuan Cai; Jianhua Zhang; Willem J de Lange; Zachery R Gregorich; Hannah Karp; Emily T Farrell; Stanford D Mitchell; Trisha Tucholski; Ziqing Lin; Mitch Biermann; Sean J McIlwain; J Carter Ralphe; Timothy J Kamp; Ying Ge Journal: Circ Res Date: 2019-10-01 Impact factor: 17.367
Authors: Jianding Cheng; David W Van Norstrand; Argelia Medeiros-Domingo; David J Tester; Carmen R Valdivia; Bi-Hua Tan; Matteo Vatta; Jonathan C Makielski; Michael J Ackerman Journal: Cardiogenetics Date: 2011-10-25
Authors: Rou-Mu Hu; Bi-Hua Tan; Kate M Orland; Carmen R Valdivia; Amber Peterson; Jielin Pu; Jonathan C Makielski Journal: Am J Physiol Heart Circ Physiol Date: 2013-02-01 Impact factor: 4.733